<DOC>
	<DOCNO>NCT02941796</DOCNO>
	<brief_summary>To investigate pharmacokinetic property safety administration HCP1105 co-administration HGP0918 , HGP0816 healthy male volunteer</brief_summary>
	<brief_title>Pharmacokinetics Safety HCP1105 Co-administration HGP0918 , HGP0816 Healthy Male Volunteers</brief_title>
	<detailed_description>The purpose study investigate pharmacokinetic property safety administration HCP1105 co-administration HGP0918 , HGP0816 healthy male volunteer</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Subjects ability comprehend objective , content study property study drug participate trial willingness sign inform consent write Healthy male volunteer , age 19 55 year . The result Body Mass Index ( BMI ) less 18.5 kg/m2 , 27.0 kg/m2 â€¢Presence medical history concurrent disease may interfere treatment safety assessment completion clinical study , include clinically significant disorder digestive system , neuropsychiatric system , endocrine system , liver , cardiovascular system Someone decline liver function Liver enzyme ( AST , ALT total bilirubin ) level exceed one half time normal upper range Somenone decline kidney function eGFR &lt; 60mL/min/1.73m2</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>